Impact of granulocyte colony stimulating factor and dose intensity in treatment of small cell lung cancer
| First author [ref. no.] | Study period | Patients n | Arm | Extensive stage % | Regime | Survival | Toxicity | ||
| Median months | 2 yr % | ≥2 neutr- % | thr. penia % | ||||||
| Woll 55 | 1990–1991 | 65 | C | 31 (10) | VCR 1 mg·m−2 day 1 | C: 16 | 15 | ||
| G | 34 (6) | IFX 5 g·m−2 day 1 | GM: 17 | 32 | |||||
| Carbo 300 mg·m−2 day 1–3 | |||||||||
| E 120 mg·m−2 day 1–2 | |||||||||
| 240 mg·m−2 day 3 | |||||||||
| S: q. 2–3 wk ×6 | |||||||||
| Chest irr: 12.5 Gy ×1 | |||||||||
| PCI: 8 Gy ×1 | |||||||||
| Furuse 56 | 1998 | 227 | C | 113 (100) | CAVLEE | ||||
| G | 114 (100) | CODE: | |||||||
| P25 mg·m−2 weekly | |||||||||
| VCR 1 mg·m−2 week 1, 2, 4, 6 | |||||||||
| ADR 40 mg·m−2 + | |||||||||
| S 80 mg·m−2 week 1, 3, 5, 7, 9 | |||||||||
| Thatcher 57 | 1993–1996 | 403 | S | 202 (23) | ADR 40 mg·m−2 day 1 | S: 11 | 8 | 83 | 25 |
| I | 201 (22) | CTX 1 g·m−2 day 1 | I: 12 | 13 | 21 | 36 | |||
| E 120 mg·m−2 day 1 | |||||||||
| 240 mg·m−2 day 2–3 | |||||||||
| S: q. 3 wk I: q. 2 wks | |||||||||
| Chest irr: After chemo. | |||||||||
| No standard regime | |||||||||
IFX: ifosphamide
CTX: cyclophosphamide
ADR: doxorubicine
Carbo: carboplatin
P: cisplatin
E: etoposide
PCI: prophylactic cranial irradiation
S: standard
I: intensified
neutr: neutropenia
VCR: vincristine